glp-1 weight loss drug market news today pharma obesity A harsh reality: weight-loss efficacy means less The Food and Drug b3 Quantity:3 Months

glp-1 weight loss drug market news today pharma obesity A harsh reality: weight-loss efficacy means less The Food and Drug b3 Quantity:3 Months

The Food and Drug Administration approved a pill version of the weight loss drug Wegovy on Monday. The pill acts as an alternative to the injectable version of Wegovy for those with

placebo in the fall of eGFR was better among patients with macroalbuminuria or in those with eGFR between 30−60 ml/min/1.73 m2,100 and in the AWARD-7 trial the effect of dulaglutide on renal clinical outcomes and eGFR decline was more pronounced in participants with macroalbuminuria at baseline.66 Likewise, in a post hoc analysis of the LEADER study those patients who experienced a 30% reduction in albuminuria during follow-up had fewer cardiovascular and renal events,101 which confirms that a reduction in albuminuria is associated with a reduction in cardiovascular and renal events.99,102 Finally, the renal benefits of arGLP-1 appear to be additive to those of iSGLT2, which is of particular interest in patients with DKD.85,86,103 Cardiovascular and renal benefits of these drugs have been also demonstrated in real-life studies.104–105 The causes of renal protection by some arGLP-1 s are unclear

b3

Quantity:3 Months

Semaglutide typically produces gradual weight loss